INS and type 2 diabetes mellitus: In a single-arm study by Petit et al., 68 individuals with type 2 diabetes (21% using insulin at baseline) were treated with liraglutide 1.2 mg once daily, resulting in a 31% RR reduction of hepatic steatosis [29].